sur OBI Pharma USA, Inc. (isin : TW0004174008)
OBI Pharma Presents Ten New Poster Sessions at AACR 2026
OBI Pharma announced its participation at the AACR 2026 Annual Meeting with ten new poster presentations showcasing advancements in Antibody-Drug Conjugates (ADCs) using their GlycOBI® platform. These presentations highlighted innovations with anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, as well as novel bispecific ADCs such as anti-TROP2/HER2 (OBI 201) and dual-payload ADCs (OBI 221). The GlycOBI® technology aims to improve drug-to-antibody ratios, leading to better pharmacokinetics and decreased off-target toxicity.
Additionally, the technology addresses challenges like tumor heterogeneity and multi-drug resistance. OBI Pharma plans to expand its robust conjugation platform into complex ADCs, including degrader-antibody conjugates. The AACR 2026 meeting, taking place from April 17-22 in San Diego, will allow OBI Pharma to present these developments, offering potential improved treatment options for challenging solid tumors.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de OBI Pharma USA, Inc.